You are here

Our science / Clinical Trials / Find a Trial / NCT01352793

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Back to Search Print Save as PDF Bookmark Trial

NCT01352793

Last updated on February 23, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Accelovance,Inc.
Huntsville, Alabama, 35802 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Meningococcal Meningitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
10-25 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy subjects aged 10 to 25 years.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Previous vaccination with Hepatitis A virus vaccine

- Previous vaccination with investigational meningococcal B vaccine

- History of culture-proven N. meningitidis serogroup B disease

- Any neuroinflammatory or autoimmune condition

- Any immune defect that would prevent an effective response to the study vaccine

NCT01352793
Pfizer
Completed
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Meningococcal Meningitis
Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults
NCT00879814
All Genders
18+
Years
South Miami, Florida
Meningococcal Meningitis
Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants
NCT00161928
All Genders
0+
Years
Multiple Sites
Meningococcal Meningitis
Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults
NCT00297687
All Genders
18+
Years
Multiple Sites
Meningococcal Meningitis
Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults
NCT00780806
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now